KPTI vs. BTAI, ANNX, ERAS, VERV, TBPH, LXRX, ESPR, SLRN, FBLG, and CTNM
Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioXcel Therapeutics (BTAI), Annexon (ANNX), Erasca (ERAS), Verve Therapeutics (VERV), Theravance Biopharma (TBPH), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Acelyrin (SLRN), FibroBiologics (FBLG), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical preparations" industry.
Karyopharm Therapeutics (NASDAQ:KPTI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.
Karyopharm Therapeutics received 288 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 72.05% of users gave Karyopharm Therapeutics an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.
In the previous week, BioXcel Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for BioXcel Therapeutics and 3 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.62 beat BioXcel Therapeutics' score of 0.29 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.
Karyopharm Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Karyopharm Therapeutics presently has a consensus target price of $4.80, indicating a potential upside of 395.30%. BioXcel Therapeutics has a consensus target price of $16.71, indicating a potential upside of 823.44%. Given BioXcel Therapeutics' higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Karyopharm Therapeutics.
Karyopharm Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500.
Karyopharm Therapeutics has a net margin of -104.18% compared to BioXcel Therapeutics' net margin of -8,715.72%. Karyopharm Therapeutics' return on equity of 0.00% beat BioXcel Therapeutics' return on equity.
66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 4.3% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Karyopharm Therapeutics beats BioXcel Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Karyopharm Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Karyopharm Therapeutics Competitors List
Related Companies and Tools
